Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2021

Open Access 01-12-2021 | Hepatitis A | Review

The role of SOCS proteins in the development of virus- induced hepatocellular carcinoma

Authors: Jinyan Xie, Mingshu Wang, Anchun Cheng, Renyong Jia, Dekang Zhu, Mafeng Liu, Shun Chen, XinXin Zhao, Qiao Yang, Ying Wu, Shaqiu Zhang, Qihui Luo, Yin Wang, Zhiwen Xu, Zhengli Chen, Ling Zhu, Yunya Liu, Yanling Yu, Ling Zhang, Xiaoyue Chen

Published in: Virology Journal | Issue 1/2021

Login to get access

Abstract

Background

Liver cancer has become one of the most common cancers and has a high mortality rate. Hepatocellular carcinoma is one of the most common liver cancers, and its occurrence and development process are associated with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections.
Main body
The serious consequences of chronic hepatitis virus infections are related to the viral invasion strategy. Furthermore, the viral escape mechanism has evolved during long-term struggles with the host. Studies have increasingly shown that suppressor of cytokine signaling (SOCS) proteins participate in the viral escape process. SOCS proteins play an important role in regulating cytokine signaling, particularly the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Cytokines stimulate the expression of SOCS proteins, in turn, SOCS proteins inhibit cytokine signaling by blocking the JAK-STAT signaling pathway, thereby achieving homeostasis. By utilizing SOCS proteins, chronic hepatitis virus infection may destroy the host’s antiviral responses to achieve persistent infection.

Conclusions

This review provides recent knowledge regarding the role of SOCS proteins during chronic hepatitis virus infection and provides some new ideas for the future treatment of chronic hepatitis.
Literature
1.
Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol. 2015;87:1989–99.PubMedCrossRef
2.
Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412–24.PubMedCrossRef
3.
4.
5.
Vlasova-St Louis I, Bohjanen PR. Post-transcriptional regulation of cytokine and growth factor signaling in cancer. Cytokine Growth Factor Rev. 2017;33:83–93.PubMedCrossRef
6.
Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 2001;13:389–400.PubMedCrossRef
7.
Waldmann TA, Chen J. Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy. Annu Rev Immunol. 2017;35:533–50.PubMedPubMedCentralCrossRef
8.
Budi EH, Duan D, Derynck R. Transforming growth factor-β receptors and smads: regulatory complexity and functional versatility. Trends Cell Biol. 2017;27:658–72.PubMedCrossRef
9.
Yoshimura A, Ito M, Chikuma S, Akanuma T, Nakatsukasa H. Negative Regulation of Cytokine Signaling in Immunity. Cold Spring Harb Perspect Biol. 2018;10:a028571.PubMedPubMedCentralCrossRef
10.
11.
Rakesh K, Agrawal DK. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol. 2005;70:649–57.PubMedCrossRef
12.
13.
Ko E, Kim SJ, Joh JW, Park CK, Park J, Kim DH. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett. 2008;271:240–50.PubMedCrossRef
14.
Zhang X, Wang J, Cheng J, Ding S, Li M, Sun S, Zhang L, Liu S, Chen X, Zhuang H, Lu F. An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma. J Viral Hepat. 2014;21:264–71.PubMedCrossRef
15.
Baumert TF, Schuster C, Cosset FL, Dubuisson J, Hofmann M, Tautz N, Zeisel MB, Thimme R. Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses. J Hepatol. 2016;64:968–73.PubMedCrossRef
16.
Zhao LJ, He SF, Wang W, Ren H, Qi ZT. Interferon alpha antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus. Cytokine. 2016;80:48–55.PubMedCrossRef
17.
Delgado-Ortega M, Marc D, Dupont J, Trapp S, Berri M, Meurens F. SOCS proteins in infectious diseases of mammals. Vet Immunol Immunopathol. 2013;151:1–19.PubMedCrossRef
18.
Ren JP, Ying RS, Cheng YQ, Wang L, El Gazzar M, Li GY, Ning SB, Moorman JP, Yao ZQ. HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepat. 2016;23:755–66.PubMedPubMedCentralCrossRef
19.
Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.PubMedCrossRef
20.
Gisselbrecht S. The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. Eur Cytokine Netw. 1999;10:463–70.PubMed
21.
Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997;239:439–46.PubMedCrossRef
22.
23.
Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW, Nakayama KI. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004;18:3055–65.PubMedPubMedCentralCrossRef
24.
Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J. 1995;14:2816–26.PubMedPubMedCentralCrossRef
25.
Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148–54.PubMedCrossRef
26.
Louis C, Souza-Fonseca-Guimaraes F, Yang Y, D’Silva D, Kratina T, Dagley L, Hediyeh-Zadeh S, Rautela J, Masters SL, Davis MJ, et al. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS. J Exp Med. 2020;217:e20191421.PubMedPubMedCentralCrossRef
27.
Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.PubMedCrossRef
28.
29.
30.
Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–21.PubMedCrossRef
31.
Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo j. 1999;18:1309–20.PubMedPubMedCentralCrossRef
32.
Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O’Neill LA, Hertzog PJ. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol. 2006;7:148–55.PubMedCrossRef
33.
Frobose H, Ronn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, Billestrup N. Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol. 2006;20:1587–96.PubMedCrossRef
34.
Strebovsky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. Faseb J. 2011;25:863–74.PubMedCrossRef
35.
Yu CF, Peng WM, Schlee M, Barchet W, Eis-Hubinger AM, Kolanus W, Geyer M, Schmitt S, Steinhagen F, Oldenburg J, Novak N. SOCS1 and SOCS3 target IRF7 degradation to suppress TLR7-mediated type I IFN production of human plasmacytoid dendritic cells. J Immunol. 2018;200:4024–35.PubMedCrossRef
36.
Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka T, Mori H, Iida M, Yoshimura A. the dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells. 2007;12:143–54.PubMedCrossRef
37.
McBerry C, Gonzalez RM, Shryock N, Dias A, Aliberti J. SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses. PLoS ONE. 2012;7:e38384.PubMedPubMedCentralCrossRef
38.
Villarino A, Kanno Y, O’Shea J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18:374–84.PubMedCrossRef
39.
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–46.PubMedPubMedCentralCrossRef
40.
Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An increase in expression of SOCS1 gene with increase in hepatitis C Virus Viral Load. J Interferon Cytokine Res. 2018;38:122–8.PubMedCrossRef
41.
Convery O, Gargan S, Kickham M, Schroder M, O’Farrelly C, Stevenson NJ. The hepatitis C virus (HCV) protein, p7, suppresses inflammatory responses to tumor necrosis factor (TNF)-alpha via signal transducer and activator of transcription (STAT)3 and extracellular signal-regulated kinase (ERK)-mediated induction of suppressor of cytokine signaling (SOCS)3. FASEB J. 2019;33(8):8732–44.PubMedCrossRef
42.
Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol. 2010;91:1678–86.PubMedCrossRef
43.
Vlotides G, Sörensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer CJ. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun. 2004;320:1007–14.PubMedCrossRef
44.
Liu B, Chen S, Guan Y, Chen L. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients. PLoS ONE. 2015;10:e0133800.PubMedPubMedCentralCrossRef
45.
Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Goke B, Diepolder H, Auernhammer CJ. SOCS-1 inhibits expression of the antiviral proteins 2’,5’-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun. 2005;331:543–8.PubMedCrossRef
46.
Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529–35.PubMedPubMedCentralCrossRef
47.
Frazier AD, Zhang CL, Ni L, Ma CJ, Zhang Y, Wu XY, Atia AN, Yao ZQ, Moorman JP. Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection. Viral Immunol. 2010;23:487–95.PubMedPubMedCentralCrossRef
48.
Yao ZQ, Prayther D, Trabue C, Dong ZP, Moorman J. Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein. Immunology. 2008;125:197–207.PubMedPubMedCentralCrossRef
49.
Yao ZQ, Waggoner SN, Cruise MW, Hall C, Xie X, Oldach DW, Hahn YS. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J Virol. 2005;79:15417–29.PubMedPubMedCentralCrossRef
50.
Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest. 2000;106:1239–49.PubMedPubMedCentralCrossRef
51.
Moorman J, Dong ZP, Ni L, Zhang C, Borthwick T, Yao ZQ. Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology. 2009;128:227–35.PubMedPubMedCentralCrossRef
52.
Tomer S, Chawla YK, Duseja A, Arora SK. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol. 2016;22(22):5173–82.PubMedPubMedCentralCrossRef
53.
Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. J Formos Med Assoc. 2016;115:440–4.PubMedCrossRef
54.
Pascarella S, Clement S, Guilloux K, Conzelmann S, Penin F, Negro F. Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. J Med Virol. 2011;83:1005–15.PubMedCrossRef
55.
Ahmed QL, Manzoor S, Tariq M, Khalid M, Ashraf W, Parvaiz F, Imran M. Hepatitis C virus infection in vitro triggers endoplasmic reticulum stress and downregulates insulin receptor substrates 1 and 2 through upregulation of cytokine signaling suppressor 3. Acta Virol. 2014;58:238–44.PubMedCrossRef
56.
Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499–508.PubMedPubMedCentralCrossRef
57.
Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45:1164–71.PubMedCrossRef
58.
As C. S A, S N, M S, JA J, JE H, C OF, NJ S: Hepatitis C virus (HCV)-induced suppressor of cytokine signaling (SOCS) 3 regulates proinflammatory TNF-α responses. J Leukoc Biol. 2014;96:255–63.CrossRef
59.
Xu G, Yang F, Ding CL, Wang J, Zhao P, Wang W, Ren H. MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3. Virology. 2014;462–463:343–50.PubMedCrossRef
60.
Li A, Song W, Qian J, Li Y, He J, Zhang Q, Li W, Zhai A, Kao W, Hu Y, et al. MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1. Int J Biochem Cell Biol. 2013;45:858–65.PubMedCrossRef
61.
Koeberlein B. zur Hausen A, Bektas N, Zentgraf H, Chin R, Nguyen LT, Kandolf R, Torresi J, Bock CT: Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res. 2010;148:51–9.PubMedCrossRef
62.
Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 2012;56:820–30.PubMedCrossRef
63.
Wang W, Bian H, Li F, Li X, Zhang D, Sun S, Song S, Zhu Q, Ren W, Qin C, Qi J. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. Cell Mol Life Sci. 2018;75:2627–41.PubMedCrossRef
64.
Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol. 2009;46:2640–6.PubMedCrossRef
65.
Tang Y, Chen X, Zhang Y, Tang Z, Zhuo M, Li D, Wang P, Zang G, Yu Y. Fusion protein of tapasin and hepatitis B core antigen 1827 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice. Mol Med Rep. 2014;9:1171–8.PubMedCrossRef
66.
Chen X, Liu H, Tang Z, Yu Y, Zang G. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes via cytoplasmic transduction peptide. Acta Biochim Biophys Sin (Shanghai). 2013;45:203–12.CrossRef
67.
Chen X, Tang Y, Zhang Y, Zhuo M, Tang Z, Yu Y, Zang G. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. Lab Invest. 2014;94:478–90.PubMedCrossRef
68.
Du LY, Cui YL, Chen EQ, Cheng X, Liu L, Tang H. Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J. 2014;11:51.PubMedPubMedCentralCrossRef
69.
Jj Z, Yc F, Zh Z. Y Y, CY D, S G, K W: Prognoses of patients with acute-on-chronic hepatitis B liver failure are closely associated with altered SOCS1 mRNA expression and cytokine production following glucocorticoid treatment. Cell Mol Immunol. 2014;11:396–404.CrossRef
70.
Bock CT, Toan NL, Koeberlein B, le Song H, Chin R, Zentgraf H, Kandolf R, Torresi J. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology. 2008;51:432–43.PubMedCrossRef
71.
Zhang P, Li F, Li N, Zhu Q, Yang C, Han Q, Chen J, Lv Y, Yu L, Wei P, Liu Z. Genetic variations of SOCS1 are associated with chronic hepatitis B virus infection. Hum Immunol. 2014;75:709–14.PubMedCrossRef
72.
Hu Z, Yang J, Wu Y, Xiong G, Wang Y, Yang J, Deng L. Polymorphisms in CISH gene are associated with persistent hepatitis B virus infection in Han Chinese population. PLoS ONE. 2014;9:e100826.PubMedPubMedCentralCrossRef
73.
Fu X, Song X, Li Y, Tan D, Liu G. Hepatitis B virus X protein upregulates DNA methyltransferase 3A/3B and enhances SOCS-1CpG island methylation. Mol Med Rep. 2016;13:301–8.PubMedCrossRef
74.
Teng CF, Chang HY, Tsai HW, Hsieh WC, Kuo YH, Su IJ, Lin YJ. Liver regeneration accelerates hepatitis B virus-related tumorigenesis of hepatocellular carcinoma. Mol Oncol. 2018;12:1175–87.PubMedPubMedCentralCrossRef
75.
Ou X, Mao S, Cao J, Ma Y, Ma G, Cheng A, Wang M, Zhu D, Chen S, Jia R, et al. The neglected avian hepatotropic virus induces acute and chronic hepatitis in ducks: an alternative model for hepatology. Oncotarget. 2017;8:81838–51.PubMedPubMedCentralCrossRef
76.
Xie J, Zeng Q, Wang M, Ou X, Ma Y, Cheng A, Zhao X-X, Liu M, Zhu D, Chen S, et al. Transcriptomic characterization of a chicken embryo model infected with duck hepatitis a virus type 1. Front Immunol. 1845;2018:9.
77.
Xie J, Wang M, Cheng A, Zhao X-X, Liu M, Zhu D, Chen S, Jia R, Yang Q, Wu Y, et al. DHAV-1 inhibits type I interferon signaling to assist viral adaption by increasing the expression of SOCS3. Front Immunol. 2019;10:731.PubMedPubMedCentralCrossRef
78.
Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI, Johnson HM. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol. 2007;178:5058–68.PubMedCrossRef
79.
Ahmed CM, Larkin J 3rd, Johnson HM. SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function. Front Immunol. 2015;6:183.PubMedPubMedCentralCrossRef
80.
Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, Shahinian A, Lang PA, Lang KS, Morre M, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell. 2011;144:601–13.PubMedCrossRef
Metadata
Title
The role of SOCS proteins in the development of virus- induced hepatocellular carcinoma
Authors
Jinyan Xie
Mingshu Wang
Anchun Cheng
Renyong Jia
Dekang Zhu
Mafeng Liu
Shun Chen
XinXin Zhao
Qiao Yang
Ying Wu
Shaqiu Zhang
Qihui Luo
Yin Wang
Zhiwen Xu
Zhengli Chen
Ling Zhu
Yunya Liu
Yanling Yu
Ling Zhang
Xiaoyue Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2021
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-021-01544-w

Other articles of this Issue 1/2021

Virology Journal 1/2021 Go to the issue

Review

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis

Research

Targeting the Kaposi’s sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells

Research

Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study

Short report

How home anterior self-collected nasal swab simplifies SARS-CoV-2 testing: new surveillance horizons in public health and beyond

Research

Epidemiological characteristics of four common respiratory viral infections in children

Research

Monoclonal antibodies specific for the hemagglutinin-neuraminidase protein define neutralizing epitopes specific for Newcastle disease virus genotype 2.VII from Egypt
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits